Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) CFO Alexis Desieno sold 7,324 shares of the company's stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $1.78, for a total transaction of $13,036.72. Following the sale, the chief financial officer directly owned 171,858 shares in the company, valued at approximately $305,907.24. This trade represents a 4.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Cardlytics Price Performance
CDLX stock traded up $0.07 during mid-day trading on Friday, reaching $1.87. 720,336 shares of the company traded hands, compared to its average volume of 999,467. Cardlytics, Inc. has a 52-week low of $1.22 and a 52-week high of $9.48. The company has a market capitalization of $97.91 million, a P/E ratio of -0.52 and a beta of 1.21. The company has a debt-to-equity ratio of 2.62, a current ratio of 1.19 and a quick ratio of 1.19. The company has a fifty day moving average price of $1.81 and a 200-day moving average price of $2.38.
Hedge Funds Weigh In On Cardlytics
Several hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its stake in Cardlytics by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 402,552 shares of the company's stock worth $1,493,000 after purchasing an additional 12,209 shares in the last quarter. Brooktree Capital Management raised its position in shares of Cardlytics by 4.5% in the fourth quarter. Brooktree Capital Management now owns 175,210 shares of the company's stock worth $650,000 after buying an additional 7,568 shares in the last quarter. Intech Investment Management LLC raised its position in shares of Cardlytics by 31.3% in the fourth quarter. Intech Investment Management LLC now owns 19,310 shares of the company's stock worth $72,000 after buying an additional 4,607 shares in the last quarter. Virtu Financial LLC bought a new stake in Cardlytics during the fourth quarter valued at $62,000. Finally, Geode Capital Management LLC grew its position in Cardlytics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,060,739 shares of the company's stock worth $3,936,000 after buying an additional 7,561 shares in the last quarter. Hedge funds and other institutional investors own 68.10% of the company's stock.
Wall Street Analyst Weigh In
CDLX has been the topic of several research reports. Evercore ISI lowered their price target on shares of Cardlytics from $4.00 to $3.00 and set an "in-line" rating on the stock in a research report on Thursday, March 13th. Lake Street Capital cut their price objective on shares of Cardlytics from $3.00 to $2.50 and set a "hold" rating for the company in a report on Thursday, May 8th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Cardlytics in a research note on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $3.50.
Get Our Latest Stock Analysis on Cardlytics
About Cardlytics
(
Get Free Report)
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Featured Stories

Before you consider Cardlytics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.
While Cardlytics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.